echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Simcere Pharma and Vivoryon collaborated to target N3pE amyloid protein SIM0408 approved for clinical use

    Simcere Pharma and Vivoryon collaborated to target N3pE amyloid protein SIM0408 approved for clinical use

    • Last Update: 2022-05-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 28, Simcere Pharma and Vivoryon Therapeutics of Germany jointly announced that SIM0408, a new drug under development for Alzheimer's disease jointly developed by the two parties in China, has been approved by the Center for Drug Evaluation of the State Drug Administration to enter clinical trials in China


    SIM0408 is a differentiated oral small molecule investigational drug candidate for Alzheimer's disease with the potential to address multiple key AD pathological mechanisms in a unique mode, including Aβ pathology, neuroinflammation and synaptic damage


    SIM0408 blocks glutaminyl cyclase (QPCT) action associated with AD pathology


    Reference source: [1] Simcere official website

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.